Cancer Channel
Topics
Medications
Quicklinks
Related Channels

Bendamustine

If you have chronic lymphocytic leukemia or non-Hodgkin's lymphoma, your healthcare provider may recommend chemotherapy treatment with bendamustine. This prescription medicine works to kill cancer cells by disrupting their multiplication process. Possible side effects may include diarrhea, fatigue, and vomiting. This drug is given intravenously for two days in a row every 21 to 28 days.

What Is Bendamustine?

Bendamustine (Treanda®) is a prescription medication approved to treat certain cancers of the blood cells. Specifically, it is used in people who have been newly diagnosed with chronic lymphocytic leukemia (CLL) or for those who have a type of non-Hodgkin's lymphoma (NHL) that has become worse despite treatment with another medication. It belongs to a group of drugs known as alkylating agents.
 
(Click What Is Bendamustine Used For? for more information on this topic, including possible off-label uses.)
 

Are There Side Effects?

Just like any medicine, bendamustine can cause side effects. As with other chemotherapy medicines, the side effects can be significant and potentially serious. Talk with your healthcare provider about ways to prevent or lessen reactions to this drug.
 
Common side effects of bendamustine include but are not limited to:
 
  • A decrease in blood cell counts
  • Nausea
  • Fatigue
  • Vomiting
  • Diarrhea.
 
(Click Bendamustine Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
 
7 Natural Ways to Reduce Your Cancer Pain

Bendamustine Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.